Silane-Modified Glucopyranose Polymers for Stable Biodegradable Matrices
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Biodegradable polymers used in medical devices face challenges in forming stable, durable matrices that can effectively release bioactive agents and degrade compatibly within the body, while maintaining structural integrity and biocompatibility.
Innovation Solution
Development of silyl ether-modified hydrophobic α(1→4)glucopyranose polymers that include pendent hydrophobic groups and silyl ether groups, allowing for improved matrix formation through crosslinking and degradation, enabling the creation of stable polymeric matrices for medical applications such as coatings, microparticles, and implants that can release bioactive agents and degrade naturally.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional biodegradable polymers are used to form polymeric matrices, then the matrices can be degraded in the body without explantation, but the matrices lack sufficient durability and stability
Solution Approach 1:
The patent creates a composite polymeric matrix by combining hydrophobic α(1→4)glucopyranose polymer chains with silane crosslinking agents. The silane groups form crosslinks between polymer chains, creating a composite structure that maintains the biodegradability of the polysaccharide while adding structural durability and stability through the crosslinked network.
Solution Approach 2:
The patent modifies the chemical parameters of the polysaccharide polymer by introducing hydrophobic groups and silane crosslinking. These parameter changes in the polymer structure enable the matrix to achieve both durability and stability while maintaining its biodegradable nature, resolving the contradiction between longevity and compositional stability.
2Strength
If biodegradable polymers are used for drug delivery matrices, then the matrices can be totally degraded in the body, but the matrices do not provide sufficient structural integrity
Solution Approach 1:
The patent applies preliminary crosslinking action during matrix formation, where silane groups are activated to form crosslinks between polymer chains before implantation. This preliminary structural reinforcement ensures that the matrix achieves sufficient structural integrity while maintaining the ability to degrade completely in the body through controlled hydrolysis of the crosslinks.
Solution Approach 2:
The crosslinking density and hydrophobic group distribution are optimized locally within the polymeric matrix to provide sufficient structural integrity where needed while maintaining overall biodegradability. The local variation in crosslinking density allows different regions of the matrix to have different degradation rates, ensuring structural stability during the degradation process.
3Ease of manufacture
If silyl ether groups are introduced to promote matrix formation, then crosslinking and coating stability are improved, but the polymer synthesis complexity increases
Solution Approach 1:
The patent segments the polymer modification process into distinct steps: first introducing hydrophobic groups to the polysaccharide, then separately introducing silane crosslinking groups. This segmentation allows each modification to be optimized independently and simplifies the overall synthesis process compared to creating all functional groups in a single complex reaction.
Solution Approach 2:
The patent uses silane groups as intermediary crosslinking agents that facilitate matrix formation without requiring complex multi-step synthesis. The silane groups act as mediators between polymer chains, enabling crosslinking through relatively simple hydrolysis and condensation reactions rather than requiring complex coupling reactions.
4Reliability
If hydrophobic groups are added to α(1→4)glucopyranose polymers, then matrix durability is enhanced, but the natural degradation rate is reduced
Solution Approach 1:
The patent carefully controls the degree of hydrophobic group substitution and crosslinking density as parameters to balance durability enhancement with acceptable degradation rates. By optimizing these parameters, the matrix achieves sufficient durability for its intended application while maintaining a degradation rate that allows complete biodegradation in the body.
Solution Approach 2:
The hydrophobic groups and crosslinks are distributed non-uniformly throughout the polymer matrix, with higher concentrations in regions requiring enhanced durability and lower concentrations in regions that should degrade faster. This local quality variation allows different parts of the matrix to have different functional lifetimes, balancing overall durability with degradation rate.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The silyl ether-modified hydrophobic α(1→4)glucopyranose polymers enhance the durability and biocompatibility of polymeric matrices, facilitating controlled release of bioactive agents and ensuring natural degradation, thus addressing the limitations of existing biodegradable polymers in medical devices.
Implementation Method 1
the silyl ether groups can hydrolyze upon contact with water and bond to a target component
Implementation Method 2
the silyl ether groups can undergo reaction to promote matrix formation... Exemplary targets include a material on the surface of a device, or a silyl ether group from another silyl ether-modified hydrophobic α(1→4)glucopyranose polymer such as to provide polymer-polymer crosslinking
Data Source
AI summary
Silane-functionalized hydrophobic α(1→4)glucopyranose polymers and polymeric matrices are described. Biodegradable matrices can be formed from hydrophobic α(1→4)glucopyranose polymers with reactive pendent silyl ether groups. Reaction of the silyl ether groups provides improved matrix formation through bonding to a device surface of a device, polymer-polymer crosslinking, or both. Biodegradable matrices can be used for the preparation of implantable and injectable medical devices, including those that release a bioactive agent.